Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating Biomarkers

David Ting's Biography

David Ting, Assistant Professor Of Medicine, Harvard Medical School

David Ting, M.D. is an Assistant Professor of Medicine at Harvard Medical School and a physician scientist at the Massachusetts General Hospital (MGH) Cancer Center. Dr. Ting received his B.S. in chemical engineering and biology from the Massachusetts Institute of Technology in 1999. He then went on to complete his medical degree in 2004 at Harvard Medical School in the Health Science and Technology (HST) program. During his medical training, he did biomedical research with Dr. Robert Langer at MIT working on polymer based nucleic acid delivery systems, and also completed a Howard Hughes Medical Institute fellowship with Dr. George Daley at the Whitehead Institute working on the differentiation of embryonic stem cells into hematopoietic stem cells. He did his residency in internal medicine at MGH followed by medical oncology fellowship in the combined Dana-Farber Cancer Institute and MGH Cancer Center program.
In 2008, he began his post-doctoral research work with Daniel Haber’s group at the MGH Cancer Center, where he began work characterizing pancreatic circulating tumor cells (CTCs) and primary tumors with RNA-sequencing. This led to his discovery of aberrant satellite non-coding RNA expression across epithelial cancers, the identification of Wnt pathway activation in pancreatic CTCs, and the characterization of pancreatic CTC heterogeneity through single cell RNA-sequencing. His laboratory utilizes single cell RNA-sequencing, CTC microfluidic technologies, and RNA in situ hybridization methodology to understand the complex transcriptional landscape of pancreatic cancer. This has provided novel insight into the pathogenesis of pancreatic cancer and novel cancer biomarkers and therapeutic targets.

David Ting Image

Single cell RNA-sequencing of Circulating Tumor Cells

Tuesday, 22 March 2016 at 08:00

Add to Calendar ▼2016-03-22 08:00:002016-03-22 09:00:00Europe/LondonSingle cell RNA-sequencing of Circulating Tumor

Circulating Tumor Cells (CTCs) are thought to be enriched for the precursors of metastasis.  The detection of CTCs has been shown to be a poor prognostic marker across a variety of malignancies.  However, the absolute number of CTCs found across technologies has revealed that CTC numbers do not necessarily correlate with tumor burden. This suggests that CTCs are heterogeneous and the complete metastatic program is not inherent to all CTCs.  To characterize the heterogeneity of CTCs, we have developed methods to perform large scale single cell RNA-sequencing of CTCs across malignancies.  In a pancreatic cancer mouse model we demonstrate that CTCs are heterogeneous and that not all CTCs are the same.  Together, our work suggests that the ability of CTCs to gain access to the vasculature is an early event in tumorigenesis and that characterizing the transcriptome of CTCs will not only provide novel predictive biomarkers, but also mechanistic insight into the metastatic cascade.

Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonRNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating